Micronutrients & recovery
Curcumin, the active compound in turmeric, reduces amyloid-beta plaques and cognitive deficits in Alzheimer's disease models by directly binding to and clearing plaques, with bioavailability issues addressed by new formulations.
Turmeric contains curcumin, which has shown promise in reducing amyloid plaques in animal models. However, standard curcumin supplements have poor bioavailability. If considering supplements, look for advanced formulations designed to improve absorption, but note that human clinical trials are still ongoing. Dietary turmeric is a safe and low-cost addition to an anti-inflammatory diet.
Like Congo red, it is an amyloid binding dye and direct inhibitor of Aβ oligomer and fibril formation that can enter the brain to directly label plaques and markedly reduce Aβ42 and plaques even in old APP Tg mice, suggesting a possible “vaccine-like” clearance (Cole et al., 2003).
Why this rating
Strong preclinical evidence in mice; human clinical trials are mentioned as in progress with new formulations.
Source
Nutrition, Brain Aging, and Neurodegeneration: Table 1.
James A. Joseph et al. · Journal of Neuroscience · 2009
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →